PARP INHIBITOR
Clinical trials for PARP INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PARP INHIBITOR trials appear
Sign up with your email to follow new studies for PARP INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough ovarian cancers: testing a powerful drug duo
Disease control Recruiting nowThis study is testing a new combination of two drugs, vismodegib and atezolizumab, for women with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based chemotherapy. The goal is to see if this drug pair can shrink tumors and control the…
Matched conditions: PARP INHIBITOR
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New-Generation cancer pill aims for fewer side effects, targets brain tumors
Disease control Recruiting nowThis study is testing a new oral drug called SPR1020 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers hope this new, more targeted drug may shrink …
Matched conditions: PARP INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New telehealth program aims to fight debilitating cancer fatigue
Symptom relief Recruiting nowThis study is testing a telehealth program called REVITALIZE to see if it can help reduce the severe fatigue that often interferes with daily life for people with advanced ovarian cancer who are taking PARP inhibitor medications. About 240 participants will be randomly assigned t…
Matched conditions: PARP INHIBITOR
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Mar 19, 2026 14:56 UTC